Order Article Reprints

Yamashita S, Sakamoto A, Shoji S, Kawaguchi Y, Wakabayashi Y, Matsunaga M, Suguro K, Matsumoto Y, Takase H, Onodera T, et al. Feasibility of Short-Term Aggressive Lipid-Lowering Therapy with the PCSK9 Antibody in Acute Coronary Syndrome. Journal of Cardiovascular Development and Disease. 2023; 10(5):204. https://doi.org/10.3390/jcdd10050204

Yamashita, Satoshi, Atsushi Sakamoto, Satoshi Shoji, Yoshitaka Kawaguchi, Yasushi Wakabayashi, Masaki Matsunaga, Kiyohisa Suguro, Yuji Matsumoto, Hiroyuki Takase, Tomoya Onodera, and et al. 2023. "Feasibility of Short-Term Aggressive Lipid-Lowering Therapy with the PCSK9 Antibody in Acute Coronary Syndrome" Journal of Cardiovascular Development and Disease 10, no. 5: 204. https://doi.org/10.3390/jcdd10050204

Yamashita, S., Sakamoto, A., Shoji, S., Kawaguchi, Y., Wakabayashi, Y., Matsunaga, M., Suguro, K., Matsumoto, Y., Takase, H., Onodera, T., Tawarahara, K., Muto, M., Shirasaki, Y., Katoh, H., Sano, M., Suwa, K., Naruse, Y., Ohtani, H., Saotome, M., ... Maekawa, Y. (2023). Feasibility of Short-Term Aggressive Lipid-Lowering Therapy with the PCSK9 Antibody in Acute Coronary Syndrome. Journal of Cardiovascular Development and Disease, 10(5), 204. https://doi.org/10.3390/jcdd10050204